Nanomedicine Penetrating Blood‐Pancreas Barrier for Effective Treatment of Acute Pancreatitis

Nanomedicine Penetrating Blood‐Pancreas Barrier for Effective Treatment of Acute Pancreatitis

Abstract Acute pancreatitis (AP) is a primary contributor to hospitalization and in‐hospital mortality worldwide. Targeted elimination of mitochondrial reactive oxygen species (mtROS) within pancreatic acinar cells (PACs) represents an ideal strategy for treating AP. However, existing drugs fail to...

Full description

Saved in:
Bibliographic Details
Main Authors: Dan Wang, Shuya Wang, Jinjin Liu, Xiaojing Shi, Tingli Xiong, Ruishi Li, Wei Wei, Liandong Ji, Qiong Huang, Xuejun Gong, Kelong Ai
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Advanced Science
Subjects:
acute pancreatitis
blood‐pancreas barriers
cGAS, mitochondrial targeting
reactive oxygen species
STING
Online Access:https://doi.org/10.1002/advs.202413925
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Acute pancreatitis (AP) is a primary contributor to hospitalization and in‐hospital mortality worldwide. Targeted elimination of mitochondrial reactive oxygen species (mtROS) within pancreatic acinar cells (PACs) represents an ideal strategy for treating AP. However, existing drugs fail to overcome the physiological barriers of the pancreas to effectively reach PACs mitochondria due to the trade‐off between conventional positively charged mitochondrial‐targeting groups and their inability to penetrate the blood‐pancreas barrier (BPB). Here, a tungsten‐based heteropolyacid nano‐antioxidant (mTWNDs) is introduced, co‐modified with tannic acid (TA) and melanin, enabling site‐specific clearance of mtROS in PACs, offering a highly effective treatment for AP. TA exhibits a strong affinity for proline‐rich type III collagen and the mitochondrial outer membrane protein TOM20. This unique property allows mTWNDs to traverse the damaged BPB‐exposing type III collagen to reach PACs and subsequently penetrate mitochondria for targeted mtROS elimination. In cerulein‐induced AP mice, mTWNDs reversed AP at 1/50th the dose of N‐acetylcysteine, suppressing PACs apoptosis and inflammation by blocking the stimulator of the interferon genes pathway activation in macrophage. This study establishes a mitochondrial‐targeting antioxidant nanomedicine strategy for AP treatment.
ISSN:2198-3844

Similar Items